We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Redx Pharma

R&D update: RXC004 and RXC007 in the spotlight

Lighthouse | 12 October 2021


Poised to disrupt existing tumour assay protocols

Update | 01 October 2021


Foundations for two healthy businesses now in place

Lighthouse | 30 September 2021

Futura Medical

A year of delivery, with key milestones achieved

Update | 30 September 2021

Allergy Therapeutics

FY21 results show continued strong growth

Update | 23 September 2021

Arecor Therapeutics

H121 results underline quality of management execution

Lighthouse | 23 September 2021

Allergy Therapeutics

VLP Peanut heading towards US Phase I studies

Update | 21 September 2021

Redx Pharma

ESMO 2021: RXC004 monotherapy Phase I study results

Update | 21 September 2021

Arecor Therapeutics

AT278 Phase I delivers better than expected results

Lighthouse | 20 September 2021

Arecor Therapeutics

Formulating the recipe for success

Initiation | 14 September 2021
397 results found.